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ABSTRACT  
Over recent years, there have been many efforts to develop the absorption rate of medications and the therapeutic efficacy of  oral dosage types. 
GRDDS for strengthen the pharmacological effects of drugs with a small uptake site, are unbalanced at pH greater than 7, are dissolved under 
acidic region, and are effective local region in the stomach. The gastro retentive systems that have the different evaluation parameter that 
according to the dosage forms. There are many criteria for the choosing of the drug used in the gastro-retardant systems as the drug should be 
sparingly stable, it should be compatible with the gastric region, and narrow absorption. In this review, we have summarized the information 
related to the various approaches for enhancing and prolonging of the dosage forms in the stomach for their extended-release of action. Also 
talking about the many natural and synthetic polymers is used in the formulation with their different grade and their ratio that affects on the 
release action. The many scientist and inventors have increased their interest in developing the novel dosage forms and they staying in the 
stomach for showing the prolonged period action. We have also discussed the novel technology are involved in the gastric rete ntion many 
companies has been developed the polymer grades for using it in the formulation for showing the retention action.  
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INTRODUCTION  
The oral route is best path for the drug administration for 
single-dose systems and it is easy for administration and 
cost-effective for developing a single dos controlled release 
or extended or sustained release dosage form the extensive 
research has been performed for making the better patient 
compliance and avoidance of repeated administration of the 
drug the highly soluble drug at acidic pH condition and lower 
solubility at pH higher than 7 resulted as a lower absorption 
window drug from intestine. The basic advantages of GRDDS 
are to enhance the bioavailability and they having site-
specific drug delivery for treating GI disorder when the drug 
bioavailability is increased then decreasing the dosing 
repetition and ultimately the minimizing GI disorder the 
disadvantages of the GRDDS is incompatible with those 
medications that irritate the gastric mucosa compared to 
conventional dosage form.[1] Formulation is to standing in 
the stomach for an indefinite time by providing a product 
material to the top part of the GI tract 
There is the various method for increasing the gastric 
retention time in the stomach such as floating systems which 
including the low density in that gas generating system, 
swelling systems in these systems the dosage form are 
floated in the gastric fluid due to density of the components 
is should be less than the density of the stomach.[2] In the 
bio adhesive system the dosage form adheres to the mucosal 
surface there are many theories are involved in these 
systems in the high-density system dosage form they remain 
in the distal section of the stomach because of the mass of 
dosage form are higher than gastric fluid. In the super porous 
hydrogel system, the dosage form is swelled due to water 
uptake through the porous by a capillary wetting 
mechanism. In the raft forming systems contains polymers 
they swell and form the in situ gel layer and they are floated 
above the gastric fluid called raft forming systems. In the 
expandable techniques, systems is swell and unfold and it 
occurs by diffusion.[4]  
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Anatomy of stomach 
The most dilated of the gastrointestinal tract is the stomach 
and it is positioned between the the esophagus and small 
intestine. The pyloric sphincter governs the opening of 
stomach in the duodenum. The stomach can be classified into 
four anatomical part namely; fundus, body, antrum, 
pylorus.[5] 
Composition of gastric content 
The stomach has a capacity is about 1.12-1.5 L, normal 
stomach possess the J shape. The larger most part of the 
stomach is the fundus area accounting for 60-80% of total 
mucosal surface. The bottom half of the fundus zone is 
segregated from the pylorus by the lower curvature angle 
forms known as Incisura angularis. the interface of pyloric 
and fundus region is not sharply detached and its also 
referred to as the transitional zone the circular fiber of 
pyloric sphincter guarded the backflow of small intestine 
contents into the stomach. Form total mucosal region 
contains 15% pyloric area and partition to two components 
pyloric antrum. Which would be relatively abbreviated 
broader, closer chamber and the pyloric canal the narrow 
tubular passage ends in the pyloric sphincter about 3 cm 
long. The pH of the napping stomach in young adults ranges 
from 1.7 to 1.3 in the elder one. The typical stomach secretes 
approximately 3 L of fluid every 24 hours and these fluids 
consists of primarily mucus, lipase enzyme, also pepsinogen, 
acid and intrinsic factors which mostly gastric secretion it 
includes, 
1.Parietal cell produces acids, Which keeps the pH of the 
stomach in the fasted state from 1 to 3.5 
2.Gastrin hormone, Which is an effective modulator of the 
development of gastric acid 
3. Pepsins that from the peptic cells created in the form of 
their pepsinogen precursor 4.Mucus, initiated from the 
surface mucosal cells and lines the gastric mucosa[6, 7] 
Function of stomach 
Primary part of the stomach is fundus, the larger part of the 
stomach is body and antrum. The storage is done by fundus 
and body, whereas the function of the antrum is grinding and 
sieving of food. the stomach consist of mucosa does not 
contain gastric pits[8] 
Migrating myoelectric complex (MMC) cycle  
In the both fasting and fed states gastric emptying are 
obtained. Nevertheless, the motility pattern varies. markedly 
in the two condition in the fasted condition it is 
characterized by an inter-digestive 4 phase as shown on 
figure 1. 
 
Figure 1:  Phase cycle 
Phase1.It is a relatively inactive 40-60 minute period with 
only occasional contractions. Phase2.Incresing numbers of 
contractions are present in phase2, which has a similar 
duration to phase1 
Phase3.This is characterized by strong peristaltic 
contractions after opening the base of pylorus and clears the 
stomach of any residual material. 
Phase4. This is a less period of transition among powerful 
action of phase3 and phase1.The process repeats every 2 
hours until the meal is eaten and fed or motility starts 
Advantages 
1.Increase the intestinal absorption 
2.Increase drug activity 
3.Formulate continue release drug delivery 
4.Providing predertermined activity 
5. Deceased product concentration changes 
6. Enhanced receptor activation selectivity[9, 10] 
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LOW-DENSITY SYSTEMS  
This systems was firstly introduced by J.DAVIS in 1968. it is 
also said as hydro dynamically balanced systems .for floating 
the bulk density should be lesser than (1.004 g/cm) [11, 12]  
Due to this, they allow to floated a dosage form for a 
lengthened time in the stomach 
They are major approaches to reaching a longer gastric 
retention time and shows higher drug bioavailability[13,14] 
Low-density systems or floating systems are of the two types 
as,[15] 
1. Non-effervescent systems 
2. Effervescent systems 
(1).Non-effervescent floating drug delivery systems 
It was firstly described by Sheth PR and Tossounlan J in 1984 
the main advantages of non-effervescent systems is the 
stability of acid or base labile drug gastric pH not affected 
floating lag time. 
The tablet was designed with a mixture of optimized solid 
dispersion and action retardant polymers/swellable 
polymers such as xantham gum and polyethylene oxide in 
the hydrodynamically balanced system contains drugs with 
gel-forming agent or swellable cellulose type hydrocolloids, 
polysaccharides and matrix-forming. Polymers help prolong 
the staying time of GI and improve the absorption of drugs. 
Microporous compartments systems consisting of drug 
encapsulation reservoirs inside pores in microporous 
compartment. The floatation chamber of trapped air allows 
the system to buoyance over gastric material in the stomach.  
(2).Effervescent floating drug delivery systems 
In these preparation including a release retardant polymers, 
ethylcellulose, eudragit L100,xantham gum, polyethylene 
oxide(PEO)N12K.[17] In that formulation the gas generating 
agent. Makes better the buoyancy of the tablet in gastro-
floating systems consists hydrophilic polymers combination. 
Nonetheless, no systematic study has yet been carried out to 
investigate the effect of sodium bicarbonate on drug release 
kinetics, so it is important to investigate its impact in the 
effervescent process on drug release kinetics of higher 
water-soluble drugs.The gas entrapped membrane was 
usually observed during storage leading to failures in floating 
and sustained release these can be overcome by the using 
glyceryl monostearate and talc as an anti-tacking agent.[18, 
19] As shown in Figure 2. 
 
Drug + Polymer 
Figure 2: Effervescent systems 
 
 (i).Gas generating systems 
The effervescent reaction among carbonate/bicarbonate 
salts, citric/tartic acid, CO2 is released in presence of water 
when the formulation is put in the beaker it will sink with a 
production of gas it rises up and floats.[20] 
(ii).Volatile liquid containing system 
It consists of the liquid in inflatable chamber like ether that 
produces gas at body temperature to causing the inflation of 
the chamber in the stomach. This inflatable chamber holds a 
pool of medicines stored in a capsule of gelatin. The capsule 
disperses the drug reservoir after ingestion together with the 
inflatable. due to this forming of gas bubbles of CO2 by 
incorporation of carbonates or bicarbonates, by contact with 
gastric region.[21] 
 (iii).Raft forming systems 
In this process, a viscous gel containing trapped carbon 
dioxide bubbles on contact with gastric fluid is created by 
carbonates or bicarbonates. Formulation often typically 
contains antacid such as aluminum hydroxide or calcium 
carbonate to minimize gastric acidity. They create a layer on 
upper of gastric fluids which are often used in GI treatment 
as with water.[22] 
HIGH DENSITY SYSTEM   
The gastric fluid density is the same as water such as 
1.004g/ml the system are retained in the stomach is possible 
when the density of systems is equal to 3 g/ml and they 
enable the system are withstand peristaltic movements in 
the stomach. By using titanium dioxide, iron powder, zinc 
oxide, barium sulfate they higher the retention period.[23, 
24] as shown in Figure 3. 
 
Drug + Polymer 
Figure 3: High Density system 
EXPANDING SYSTEM 
 For the past 3 decades, expandable gastrointestinal 
retentive dosage forms have been produced. They were 
actually designed for potential medical veterinary use, but a 
letter to boost drug therapy for humans was changed. The 
expandable GRDFs are usually a small configuration 
depends, which enables for a convenient expanded oral 
intake in the stomach and thus prohibits the travels through 
the pyloric sphincter. Dissolution of the polymers and thus 
maintain the physical integrity of the dosage form. Such 
cross-linking prevent the polymers from dissolving and thus 
preserve the physical properties of dosage type. A high 
degree of cross-linking delays the system's swelling ability to 
maintain its physical integrity for extended periods of 
time.[25] as shown in Figure 4. 
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Drug + Swellable Polymer 
Figure 4: Expanding system 
                                                   
BIO ADHESIVE SYSTEMS 
Bioadhesive means adhesion to the biological surface or to 
the mucosal surface. polymers are interacted with the 
mucosa and referred to the mucoadhesion. The mucosal 
layer consists of the high molecular weighted glycoproteins 
that contain fucose, sialic acid. The thickness of mucin gel 
layer is between 50-500 micrometer in the stomach and 15-
150 micrometer in colon region the thickness depends on the 
region and adhesive properties are depends on the 
percentage of the glycoproteins concentartion. the systems 
that bind to he epithelial cell and they increased the gastric 
residence time in the stomach it having the self-protecting 
mechanisms of GI tract the goblet cells are continuously 
producing the mucus for protective action these systems are 
used for the buccal, oral, rectal, vaginal route of 
administration.[26]  as shown in Figure 5. 
 
Drug + Mucoadhesive Polymer 
Figure 5: Bio adhesive systems 
 
SUPERPOROUS HYDROGEL SYSTEMS 
The conventional hydrogels are a very long term process and 
it may take several hours to reach the equilibrium during 
which super porous hydrogels of pore size > 100 micrometre 
swell to balance size may occur prematurely in a minute. Due 
to the rapid absorption of water by capillary wetting through 
numerous open pores interconnected Increasingly, they 
swell to a massive size and are intended to have sufficient 
mechanical strength to handle the pressure due to gastric 
contraction, which is attained through the co-formulation of 
hydrophilic particulate materials.[27] as shown in Figure 6. 
 
Drug + Highly Swellable Polymer 
Figure 6: Superporous Hydrogel Systems 
MAGNETIC SYSTEM AND SELF-UNFOLDING 
SYSTEMS 
This consists of a small inner magnet and a magnet over the 
stomach position placed on the abdomen. Such systems are a 
treatment type containing a magnetic substance, the removal 
of which is prohibits by the contact with a sufficiently strong 
magnet applied to the body's surface in the area of the 
stomach. The self-unfolding systems are the ability to 
increase mechanically in relative size to the original 
dimensions. This rise stops the dose from going through the 
pylorus and maintains its extended stomach stay. A 
medication may either be included in the gastro retentive 
system's polymer composition, or it may be included as a 
separate component. The hydrogel swells in gastric juice 
contact.[23, 28] 
NOVEL TECHNOLOGIES  
OleotecTM and SoctecTM 
OleotecTM is made specifically for drugs that demand high 
pharmacological doses that are not compatible with 
conventional forms of dosage. This system offers drugs that 
are primarily absorbed in or with a localized effect in the top 
portions of the GI tract. OleotecTM is basically a stick loaded 
gel that forms a continuous pattern on the layer of the 
stomach material. They demonstrate a long effect in the 
stomach. SoctecTM has been established for drugs to be kept 
in the stomach for an large period of time. SoctecTM is 
ingested easily. generally, the stomach contents are broken 
by peristaltic contractions and the material are rapidly 
ejected into the duodenum via the pylorus. SoctecTM could 
be held greater than nine hours in the stomach. SoctecTM 
releases the drug load at a fixed level during this process, 
enabling for ingestion in the top sections of the small 
intestine.it used for narrow absorption window 
Accordion Pill™  
Is a special gastro retentive formulation comprised of 
polymer. It is compressed into a standard size, compact 
capsule. The capsule melts when it reaches the stomach; the 
Accordion PillTM unfolds and is kept in the stomach for up to 
12 hours under frequent diets with calories. The Accordion 
PillTM delivers the drug to the top portion of the 
gastrointestinal tract in a controlled way. Accordion PillTM is 
removed from the stomach; in the intestine it is wholly 
broken down. The Accordion PillTM can incorporate 
accounts for immediate and controlled release and can 
comprise more than one API and up to 550 mg for high drug 
load. It is used for less absorption window drug from the 
class of III and IV as shown in Figure 7. 
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Figure 7: Accordion Pill™ 
 
Gastro Retentive Innovative Device (GRID) 
From this system for drug uptake only in stomach or small 
intestine. GRID was created to keep medicines in the 
stomach for a period of more than eight hours. Longer 
stomach availability enhances the uptake of drugs. The tablet 
provides a combo of immediate and prolonged drug release 
profiles, and enhancing patient compliance. formation of 
dosage form with multi-layer coating GRID retains its shape 
and shape during the phase of intense gastric movements in 
order to release medication in a controlled way. Therefore, 
plasma concentrations of drugs are retained for a longer 
period of time in the therapeutic range; hence this mode of 
dosage can be used as an "Once-a-day" method. Using this 
creative medication form, expected release of drugs can be 
tailored to attain an instant and slow release pairing. 
Retention of the medication type near the uptake site can 
help to minimize the dose and therefore the side effects For a 
lot of oral drugs. Except for instant release and some 
prolonged release preparation moves through the top 
section  GI tract in about three hours after admission.as 
shown in Figure 8. 
 
Figure 8: Gastro Retentive Innovative Device 
Multiple polymer hydrophilic matrix technology 
It is for the extended release of metformin hydrochloride as a 
gastro-retardant delivery system. The polymers are a new 
mixture of hydrophilic non-ionic and ionic polymers 
Together with the polymers, metformin hydrochloride 
granules are condensed into tablets in a ratio designed to 
provide pH-independent drug release from the tablet. The 
specific release control properties of the polymer 
compounds enable the consistent and full release of 
metformin hydrochloride from the stomach to the jejunum 
without gastric pH fluctuations. When the digestive fluids 
interact with the tablet Metformin absorbs water hydrates 
and forms a swelling gelatinous matrix. The drug from the 
matrix takes place in a controlled environment by a cycle of 
dissolution of the drug and subsequent dissemination by the 
gel matrix. As tablet get expand they stay in stomach and 
show longer period of release. This show achieved clear and 
observable results: optimum absorption; less irritation; 
improved levels of plasma; and improved bioavailability 
Acuform® systems 
This systems are specially for targeted and controlled release 
action of drug The specific swelling polymers of Acuform 
technology allow the tablet to be kept in the stomach for 
about eight to ten hours. The active ingredient of the tablet is 
continuously administered to the upper GI tract at the 
optimal rate and duration during this phase. It provides the 
opportunity for greater effectiveness of treatment and 
improved tolerability of medication with the simplicity of 
one or two doses per day. In this technology that using drug 
may be in the combination. This innovation can in particular 
show to be an appropriate delivery method for compounds 
consumed in the top GI area, By means of active transport 
mechanisms, un-dissolved in water, irritating to stomach 
mucosa and they are unsuitable for bottom part of stomach it 
is highly efficacious when plasma level get varies this 
systems involved economical API that approved by FDA. For 
formation of dosage that uses high speed equipment  
Gastrointestinal permeation enhancement 
technology and Micropump 
A innovative approach provides for the transformation of 
drugs usually available injectable into oral formulations and 
increases the absorption of existing oral drugs.it used for 
bioavailability enhancer. Micropump that containing 
microparticles ranges from 5,000 to 10,000 each capsule or 
tablet.200-500 micron in size and show the release rate for 
extended period of time they are release in GI tract for up to 
24 hr. improves the efficacy, reduced the toxicity 
EUDRATEC ® GRS 
It is an Evonik patent-pending product that increases 
nutritional supplement gastro retention. This is necessary 
when maintained in the stomach for a larger time for health 
ingredients that are most active. For this reason, EUDRATEC 
® GRS was designed to maximize the time of in the stomach 
EUDRATEC ® GRS technology ensures that ingredients are 
gradually released into the stomach by allowing the 
flattening of substance-bearing capsules on gastric fluid. 
EUDRAGUARD ® command and has been demonstrated in 
vitro in bio-related media EUDRATEC® GRS is applicable for 
water-soluble agent 
 Uptake at upper section 
 Compatible in stomach not in intestine 
The EUDRATEC ® GRS system works by incorporating with 
active ingredient and the gas producing agent. The capsule is 
coated with EUDRAGUARD ® control and other excipients. 
The outer layer is porous when enveloped in gastric acid, 
causing small amounts of carbon dioxide gas to escape. 
Release control is obtained by EUDRAGIT ® NM 30 D coating 
the capsule[28] as shown in figure 9. 
 
Figure 9: Eudratec GRS 
EXCIPIENTS USED IN FLOATING SYSTEMS  
(1)Hydrocolloids- 
Hydrocolloids are the agent that having the capacity to 
forming the gel and. It gets swell when the gastric fluids are 
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in contact. e.g- Pectin, agar, HPMC, ethylcellulose, sodium 
alginates. 
(2)Release rate accelerants- 
It is an agent that increases the rate of drug release e.g-
lactose, mannitol 
(3)Release rate retardant- 
It is an agent that retards the release action of the drug by 
decreasing the solubility by using the substance like calcium 
phosphate, magnesium striate, and talc. 
(4)Buoyancy increasing agent- 
For increasing or enhancing the buoyancy by using the low-
density materials like ethylcellulose 
(5)Effervescent agent-  
This is the agents that produce carbon dioxide by contact 
with the acidic medium.in floating systems, the gas 
generating agent like citric acid, sodium bicarbonate are 
used.[21] 
POLYMERS USED IN GASTRIC RETARDANT 
SYSTEMS 
There are two types of polymers are used in the formulation 
it may be the naturally occurring or may be synthetic or may 
be the semi-synthetic used for the coating action, release 
retardant action, synthetic polymers are may be purely 
synthetic or either processed from natural resources. 
Chitosan 
Chitosan is the natural swellable polymers. chitosan is the N-
deacetylated derivatives of chitin. chitosan that contains the 
primary amino group and these primary amino group are 
shows controlled release action, mucoadhesive properties, in 
-situ gelation, enhanced the permeability chitosan having the 
non-toxic, biodegradable, biocompatible polymer, use of the 
chitosan is for oral extended-release tablet it can be either by 
granulation, or simply direct compression method.[29] 
Sheth et.al, formulate and evaluate microspheres of 
levetiracetam by using chitosan about 0.5-8% of Chitosan is 
used to arrange microspheres demonstrating continued 
release of drugs and floating for > 8 hours[30]  
 Subhojit et.al,(2012)Develope and analyses a floating tablet 
of cefixime trihydrate presence of the chitosan and they 
show excellent results on the hardness, friability, thickness, 
weight variation and also sows the good results on drug 
release and floating time.[31] 
Preparation of floated tablet of Tapentadol HCL by using 
chitosan they show the release retardant action on the drug 
and also effect on the drug release, floating time, and other 
post-compression evaluation and about 28% chitosan shows 
the sustained release action[32, 33] 
HPMC 
HPMC contains methoxy and hydrolpropoxy groups having 
the molecular weight 10000-1500000 Dalton. it is dissolve in 
the water they forms colloidal solution. Certain grades are 
soluble in acetone. 
It is acts as a bioadhesive, coating activity, controlled release 
capacity, emulsifying agent, thickening agent, they are widely 
used in the oral, opthlmic, nasal, and topical formulation or 
oral preparation, they are used for the tablet binder, coating 
solution for extended-release of the tablet for release 
retardant action the high viscosity grade is used. The HPMC 
grade involved in the liquid preparation as a category of 
suspending and viscosity increasing agent of concentration 
0.25-5.0% for the film coating about 2-2.0% of polymer are 
used they are compatible at pH 3-11 and the gelation 
temperature as 50-90°C depending on grade and its amount 
to be used there are three different HPMC grade as E5, E50, 
and K4M[34, 35] formulate the gastro-retentive controlled 
released tablet by using verapamil HCL as a model drug 
using polymers such as HPMC and xantham gum 3:2ratio and 
they show 95.39% drug release in 24 hr[36, 37] 
 
Table 1: Various grade HPMC 
HPMC Grade Viscosity 2% mPa.sa Molecular. Weight kDa Release mechanism 
HPMCK100M 100,000 1150 Swelling/Diffusion 
HPMCK15M 18,000 750 Swelling/Diffusion 
HPMCK4M 4000 500 Swelling/Diffusion/Erosion 
HPMCK100LV 100 120 Erosion 
 
 
Eudragit 
Eudragit is amorphous. eudragit obtained from 
polymerization of acrylic acid and methacrylic acids are 
mostly used for coating materials and taste-masking agents 
in oral dosage forms by spray atomization techniques. and 
there glass transition temperature is 90-150°C.it is non-
biodegradable, non-absorbent, and non -toxic in nature are 
of the two grades of the polymer as  L and S. L is dissolved at 
pH6 for coating grade S dissolved at pH 7 used for colon 
targeted systems. RS and RL containing a quaternary amino 
group and they used for sustained release. eudragit E unable 
to dissolved at pH 5 and they prohibits the initiation of drugs 
at saliva eudragit are in the various forms such as 
dispersion, organic solution, granular, powder. According to 
grade we have discussed there solubility, description, and 
there application. 
Punitha et al,.(2010) They prepared floating microsphere by 
using ranitidine HCL as a drug and using two polymers such 
as HPMC and Eudragit grade E-100 with various ratio by 
using these and they achieved an extended-release in GI 
tract results as increased the absorption and enhanced the 
bioavailability. 
Eudragit RL100 floated faster than Eudragit RS100[38, 39] 
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Table 2: Various grade of eudragit 
Immediate Release Colon Targeting Delayed Release 
 E 100  FS 100  L 100 
 E PO  S 100 L 100-55 
 E 12,5 - L 12,5 
 
Ethylcellulose 
Ethylcellulose is derived from the cellulose-containing the 
hydroxyl groups used for the microencapsulation, white in 
color, odourless, tasteless with having melting point 240-
255°C it is non-biodegradable, in nature, non-toxic, non-
irritant they having three different grades as K, N and T type 
in which K type containing 44.47.9% of ethoxy group, N 
containing 48-49.5% and T type containing 49.6-51%. 
Pande et al,. prepared the floating microspheres using 
cefpodoxime proxetil as a model drug and using two 
polymers such as ethylcellulose and HPMC they taking with 
varying concentrations and from that concluded as EC 
concentration also increases the efficacy of trapping.[40] 
S. Chandran et al,. Formulate matrix tablet of ibuprofen using 
rate-controlling polymers such as ethylcellulose to reduces 
the gastric irritants and prohibites the initiation of drug in 
the acidic area of stomach 14-16 Hr[41] 
Guar gum   
It is obtained from natural sources from the species of 
Cyamopsis tetragonolobus it is non-ionic in nature[42] 
Guar gum containing the hydroxyl groups it is 
polysaccharides having molecular weight 50,000-
8,000,000.If they are dissolved in water they show the 
gelling properties and show the sustained release action.[43, 
44]  
Kanwar et al.,(2015) formulate the pregabalin floating tablet 
using a different concentration of the natural polymers and 
they show the higher floating time grether than 24 Hr and 
show extended-release action.[45] 
Xanthan gum 
It is heteropolysaccharides in nature getted from aerobic 
fermented carbohydrates from species of Xanthomonas 
compestris it contains glucose, glucuronic acid, and 
mannose. For formulation to increase or decreases the drug 
release it is not used or shows the sustained release of drug 
in the zero-order kinetics.[46, 47] 
Formulate and evaluate the GRDDS tablet of domperidone 
by using xantham gum and guar gum and they show good 
swelling properties and show drug activity for greater than 
12 Hr.[48] 
 Formulate and evaluate gastro retentive norfloxacin floating 
tablet for increasing gastric residence time and enhancing 
bioavailability. For controlled release action using polymer  
HPMC, and xanthan gum increased the buoyancy 
behaviours.[49] 
Pectin 
Pectin is a biopolymer they have the capacity to forming the 
gel. pectin obtained from the cell wall of the plant. It is 
bioadhesive in nature.[50] Pectin shows sustained release 
action but also shows a drug carrier in targeting therapy[51, 
52] 
Satheesh babu et al,.(2016) formulate the calcium pectinate 
gel beads using famotidine as a model drug using low 
methoxy pectin and HPMC and thus they show sustained 
release action 
 
Table 3: Polymers in different dosage form. 
Sr.No. Dosage Form Polymer used 
1 Tablets Xanthan Gum, Karaya Gum, Guar Gum, Carrageenan, Hydroxypropyl 
Methylcellulose (HPMC K4M,  HPMC K100M) HPMC E15LV, HPMC E50LV, HPMC 
K100LV, Polyvinyl Pyrrolidone (PVP K30) HPMC K15M, Carbopol, Sodium 
Carboxymethyl Cellulose, PVP K30 Psyllium Husk, Crospovidone 
2 Microspheres Ethylcellulose , Eudragit RL100, Cellulose Acetate 
3 Matrix Tablet HPMC K4M, HPMC K15M, HPMC K100K, Ethyl Cellulose. 
4 Superporous Hydrogel HPMC, Carbopol 934P,Ethyl Cellulose, Chitosan, Sodium Carboxymethyl Cellulose 
5 Microballoons HPMC K4M, Ethyl Cellulose 
 
CONCLUSION: 
Gastro retentive is the most favourable approach for delivery 
of the specific quality and quantity of the drug for some long 
term disease treatments on these many approaches has been 
developed in these delivery systems for the site-specific and 
disease-specific action of the molecules in these technologies 
using the many polymeric condition that according to the 
site-specificity and their effectiveness. According to type of 
systems and there dosage forms the polymer selection and 
there concentration is to be different. If the high-density 
polymer used then the technology or approaches in GRDDS is 
change. Many synthetic, non-synthetic, and naturally 
occurring intermediates are to be used. Many of the 
formulation are involved in market according to the systems 
and dosage form which are they are in may be tablet, beads, 
gel, capsule forms. 
REFERENCES: 
1.Patil H, Tiwari RV, Repka MA. advancements in bioadhesive 
floating drug delivery systems: A mini-review. J Drug Deliv Sci 
Technology 2016; 31:65-71. 
2.GhoshD.Ghosh R. Floating drug delivery systems:review. Int J 
Pharm Med 2013;35:10-15. 
4.Streubel A, Siepmann J, Bodmeier R. Drug delivery to 
gastroretentive technologies. Currt opini in pharmacology. 2006; 
6(5):501-8. 
5.Singh B et al. QbD-enabled development of novel stimuli-
responsive gastroretentive systems of acyclovir for improved patient 
Pund et al                                                                                                               Journal of Drug Delivery & Therapeutics. 2020; 10(1):139-146 
ISSN: 2250-1177                                                                                  [146]                                                                                 CODEN (USA): JDDTAO 
compliance and biopharmaceutical performance. AAPS 
PharmSciTech. 2016; 17(2):454-65. 
6.Malpure PS,Chavan BR. Gastroretentive Drug Delivery SystemS. 
wjpps. 2019; 8(3):506-28. 
7.Tomar A, Upadhyay A, Gupta S, Kumar S. An Overview on 
Gastroretentive Drug Delivery System: Current Approaches and 
Advancements. Curnt Research in Pharma Sci 2019; 9(01)12-6. 
8.Khanvilkar K, Donovan MD, Flanagan DR. Drug transfer through 
mucus. Adv drug delivery reviews. 2001; 48(2-3):173-93. 
9.Aspden TJ et al. Chitosan as a nasal delivery system. Journal of 
pharmaceutical sciences  1997; 86(4):509-13. 
10.Garg R. Progress in controlled gastroretentive delivery systems. 
Tropical jrnal of pharma research 2008; 7(3):1055-66. 
11.Gunda RK. Formulation Development and Evaluation of Gastro 
Retentive Drug Delivery Systems-A Review. Journal of Pharmacy 
Research 2017; 8(1):11-20. 
12. More S, Gavali K, Doke O, Kasgawadek P. Gastroretentive Drug 
Delivery System. Journal of Drug Delivery and Therapeutics 2018; 
8(4):24-35. 
13.Kumar M. Approaches and Recent Patents on Gastroretentive 
Drug Delivery Systems. Recent patents on drug delivery & 
formulation 2018; 12(2):84-92. 
14.Badoni A. Review on gastro retentive drug delivery system. The 
pharma innovation. 2012; 1(8, Part A):32. 
15.Tripathi P, Ubaidulla U, Khar RK. Floating drug delivery system. 
IJRDPL. 2012; 1:1-10. 
16.Kim S et al. Preparation and evaluation of non-effervescent 
gastroretentive tablets containing pregabalin. International journal 
of pharmaceutics. 2018; 550(1-2):160-9. 
17.Meka VS, Li CE, Sheshala R. Design effervescent floating drug 
delivery system of theophylline using response surface 
methodology. Acta Pharma. 2016; 66(1):35-51. 
18.Thapa P, Jeong S. Effects of formulation and process variables on 
gastroretentive floating tablets. Pharmaceutics. 2018;10(3):161. 
19.Kriangkrai W et al. Impact of anti-tacking agents on properties of 
gas-entrapped membrane and effervescent floating tablets. AAPS 
PharmSciTech. 2014; 15(6):1357-69. 
20. Parajapati S, Maurya S, Das M, Tilak VK, Verma KK, Dhakar RC. 
Potential Application of Dendrimers in Drug Delivery: A Concise 
Review and Update. Journal of Drug Delivery and Therapeutics, 2016; 
6(2):71-88. 
21.Tripathi J, Thapa P. Review on gastroretentive drug delivery 
systems. Pharmaceutics. 2019; 11(4):193. 
22.Shah S, Patel J, Patel N. floating drug delivery system: A review. 
Int J Pharm Tech Res. 2009; 1(3):623-33. 
23.Bardonnet P, Faivre V. Gastroretentive dosage forms: Overview 
Helicobacter pylori. Journal of controlled release. 2006; 111(1-2):1-
18. 
24.Deshpande AA, Shah NH. Development of a novel controlled-
release system for gastric retention. Pharmaceutical research. 1997; 
14(6):815-9. 
25.Singh B, Chakkal SK, Ahuja N. Formulation and optimization of 
controlled release mucoadhesive tablets. AAPS PharmSciTech. 2006; 
7(1):E19-E28. 
26.Nayak AK, Malakar J. Gastroretentive drug delivery technologies. 
Journal of Pharmaceutical Education & Research. 2010; 1(2). 
27.Nayak AK, Das B, Maji R. Gastroretentive systems of ofloxacin. 
Saudi Pharmaceutical Journal. 2013; 21(1):113-7. 
28.Chudiwal V, Shahi S, Chudiwal S, Ahale D. Innovative 
Technologies for Gastro-Retentive. Asin Jrnl of Pharma Edu and 
Research. 2017; 6(4):22-8. 
29.Kas HS. Chitosan: In microparticulate systems. Journal of 
microencapsulation. 1997; 14(6):689-711. 
30.Kaushik AY, Tiwari AK. Role of excipients and polymeric 
advancements in floating drug delivery systems. Int jrnl of pharma 
invest. 2015; 5(1):1. 
31.Bandana S, Jovita K, Manisha P. Formulation floating 
microspheres of famotidine. Metabolism. 2010; 3:4. 
32.Kumar MNR. A review of chitin and chitosan applications. 2000; 
46(1):1-27. 
33.Ali A, Shahid MA, Hossain MD, Islam MN. Antibacterial bi-layered 
polyvinyl alcohol (PVA)-chitosan blend nanofibrous mat loaded with 
Azadirachta indica (neem) extract. International journal of biological 
macromolecules. 2019; 138:13-20. 
34.Sungthongjeen S, Sriamornsak P. Design of floating HPMC matrix 
tablets. Advanced Materials Research; 2011: Trans Tech Publ. 
35.Zema L, Maroni A. Different HPMC viscosity grades as coating 
agents for an oral time and/or site‐controlled delivery system. 
Journal of pharmaceutical sciences. 2007; 96(6):1527-36. 
36.Karthikeyan D, Karthikeyan M. Effect of different viscosity grades 
of HPMC on drug release profile. J Pharm Res. 2008; 1(1):23-8. 
37.Roy H, Brahma CK. Formulation and design of sustained release 
matrix tablets of metformin hydrochloride. International Journal of 
Applied and Basic Medical Research. 2013; 3(1):55. 
38.Thakral S, Thakral NK, Majumdar DK. Eudragit®: a technology 
evaluation. Expert opin on drug delivery. 2013; 10(1):131-49. 
39.Nikam VK, Kotade K. Eudragit a versatile polymer: a review. 
Pharmacologyonline. 2011; 1:152-64. 
40.Pande AV, Vaidya PD. In vitro and in vivo evaluation of floating 
microspheres of cefpodoxime proxetil. Int J Pharm Biomed Res. 
2010;1(4):122-8. 
41.Chandran S, Asghar LF. Design and evaluation of ethyl cellulose 
based matrix tablets of ibuprofen . Indian journal of pharmaceutical 
sciences. 2008; 70(5):596. 
42.Krishnaiah Y, Karthikeyan R. A three-layer guar gum matrix tablet 
for oral controlled delivery of highly soluble metoprolol tartrate. Int 
jrnal of pharma. 2002; 241(2):353-66. 
43.Sharma G, Sharma S, Kumar A. Guar gum review. Carbohydrate 
polymers. 2018; 199:534-45. 
44.Kumar SA, Vivek D, Vandana A. polymers used in floating drug 
delivery system. Journal of Pharma and Sci Innovation. 2012; 
1(3):11-5. 
45.Kanwar N, Kumar R. Preparation of floating tablets of pregabalin. 
Drug development and industrial pharmacy. 2016; 42(4):654-60. 
46.Prakash U, Singh L, Sharma V. Role of xanthan gum in 
gastroretentive drug delivery system: An overview. Int Res J Pharm. 
2013; 4(4):35. 
47.Panda S, Sailada NS, Devi B, Pattnaik S, Maharana L. Design of 
Floating Drug Delivery Systems: An Update on Polymeric 
Advancements with Special Reference from Natural Origin. 
48.Gandhi A, Verma S, Imam SS, Vyas M. A Review On Techniques 
For Grafting Of Natural Polymers And Their Applications. Plant 
Archives. 2019; 19(2):972-8. 
49.Bomma R, Naidu RS.gastroretentive norfloxacin floating tablets. 
Acta pharmaceutica. 2009; 59(2):211-21. 
50.Sriamornsak P. pectin in oral drug delivery. Expert opinion on 
drug delivery. 2011; 8(8):1009-23. 
51.Thakur BR, Singh RK. pectin—a review. Critical Reviews in Food 
Science & Nutrition. 1997; 37(1):47-73. 
52.Sundar Raj A, Rubila S. A review on pectin. Scientific reports. 
2012; 1:550-1. 
 
 
